Arch Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing an approach to stop bleeding (hemostasis), control leaking (sealant), and manage wounds during surgery, trauma, and interventional care. It is developing products based on a self-assembling barrier technology platform for patients. The company markets medical devices, such as AC5 Advanced Wound System and AC5 Topical Hemostat in the United States and Europe. Its development stage product candidates include AC5-G, AC5-V, and AC5 Surgical Hemostat and others. The company was founded in 2006 and is based in Framingham, Massachusetts. On April 18, 2025, Arch Therapeutics, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.